Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Impact of ezetimibe on atherosclerosis: is the jury still out?

Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ.

Mayo Clin Proc. 2009 Apr;84(4):353-61. doi: 10.1016/S0025-6196(11)60545-4. Review.

2.

Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.

Mascitelli L, Pezzetta F, Goldstein MR.

Arch Med Res. 2010 Nov;41(8):649-50. doi: 10.1016/j.arcmed.2010.10.008.

PMID:
21199735
3.

Pleiotropic effects of ezetimibe: do they really exist?

Kalogirou M, Tsimihodimos V, Elisaf M.

Eur J Pharmacol. 2010 May 10;633(1-3):62-70. doi: 10.1016/j.ejphar.2010.02.003. Epub 2010 Feb 10. Review.

PMID:
20152830
4.

Role of ezetimibe in the management of patients with atherosclerosis.

Hamilton P.

Coron Artery Dis. 2009 Mar;20(2):169-74. doi: 10.1097/MCA.0b013e32831edd4c. Review.

PMID:
19106797
5.

Ezetimibe and vascular endothelial function.

Ikeda S, Maemura K.

Curr Vasc Pharmacol. 2011 Jan;9(1):87-98. Review.

PMID:
21044017
6.

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.

Jeu L, Cheng JW.

Clin Ther. 2003 Sep;25(9):2352-87. Review.

PMID:
14604738
7.

Ezetimibe and vascular inflammation.

Ishibashi T, Takeishi Y.

Curr Vasc Pharmacol. 2011 Jan;9(1):99-108. Review.

PMID:
21044014
8.

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ.

J Am Coll Cardiol. 2008 Dec 16;52(25):2198-205. doi: 10.1016/j.jacc.2008.10.031.

9.

The impact of ezetimibe on endothelial function and other markers of cardiovascular risk.

Bass A, Hinderliter AL, Lee CR.

Ann Pharmacother. 2009 Dec;43(12):2021-30. doi: 10.1345/aph.1M302. Epub 2009 Nov 17. Review.

PMID:
19920161
10.

Ezetimibe: a selective cholesterol absorption inhibitor.

Nutescu EA, Shapiro NL.

Pharmacotherapy. 2003 Nov;23(11):1463-74. Review.

PMID:
14620392
11.
12.

Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years.

Lioudaki E, Ganotakis ES, Mikhailidis DP.

Curr Vasc Pharmacol. 2011 Jan;9(1):62-86. Review.

PMID:
21044019
14.

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel.

Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, Monkman D, Patel V, Pittard J, Schachter M.

Curr Med Res Opin. 2005 Jun;21(6):959-69.

PMID:
15969896
15.

Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.

Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E; Ezetimibe Study Group.

J Womens Health (Larchmt). 2004 Dec;13(10):1101-7.

PMID:
15650343
16.

Effects of ezetimibe on atherosclerosis in preclinical models.

Davis HR Jr, Lowe RS, Neff DR.

Atherosclerosis. 2011 Apr;215(2):266-78. doi: 10.1016/j.atherosclerosis.2011.02.010. Epub 2011 Feb 17. Review.

PMID:
21397230
17.

Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.

Hiro T, Hirayama A, Ueda Y, Komatsu S, Matsuoka H, Takayama T, Ishihara M, Hayashi T, Saito S, Kodama K; ZIPANGU investigators.

J Cardiol. 2014 Dec;64(6):501-7. doi: 10.1016/j.jjcc.2014.02.026. Epub 2014 Apr 13.

18.

Statin and ezetimibe combination therapy in cardiovascular disease.

Dembowski E, Davidson MH.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):183-8. doi: 10.1097/MED.0b013e3283295297. Review.

PMID:
19262375
19.

[Ezetimibe (Ezetrol) in patients with diabetes].

Scheen AJ, Radermecker RP.

Rev Med Liege. 2009 Dec;64(12):606-11. French.

20.

Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.

Ahmed MH, Byrne CD.

Diabetes Obes Metab. 2010 Nov;12(11):958-66. doi: 10.1111/j.1463-1326.2010.01261.x. Review.

PMID:
20880342

Supplemental Content

Support Center